PLEASANTON, Calif., Oct. 5, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 9, 2023. The event will begin at 9:00 a.m. PT and will conclude at approximately 11:00 a.m. PT.
Veeva will broadcast the presentations live on the company's investor relations website, ir.veeva.com, where a link to the archived webcast will also be available after the event.
Event: | Veeva Systems Virtual Investor Day |
Date: | Thursday, November 9, 2023 |
Time: | 9:00 a.m. PT (12:00 p.m. ET) |
Online event registration can be found on the company's investor relations website or directly at this | |
Webcast: |
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: | Media Contact: |
Gunnar Hansen | Maria Scurry |
Last Trade: | US$281.35 |
Daily Change: | -2.85 -1.00 |
Daily Volume: | 982,787 |
Market Cap: | US$45.980B |
July 23, 2025 June 25, 2025 June 11, 2025 June 04, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load